Neurocrine Biosciences, Inc. (NBIX)

NMS – Цена в реальном времени. Валюта: USD

155.80

+5.21 (3.46%)

При закрытии: May 12, 2026, 4:00 PM EDT

156.90

+1.10 (0.71%)

До открытия: May 13, 2026, 5:31 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Neurocrine Biosciences, Inc. (NBIX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Neurocrine Biosciences, Inc. (NBIX)

Neurocrine Biosciences, Inc. (NBIX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why

Neurocrine Biosciences: Core Business On Track, Soleno Deal Adds Risky Upside

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences, Inc. (NBIX) Q1 2026 Earnings Call Transcript

Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say

Neurocrine Biosciences (NBIX) Beats Q1 Earnings and Revenue Estimates

Видео

No Data

Пресс-релизы

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences Reports First-Quarter 2026 Financial Results

Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist

Search stocks

Neurocrine Biosciences, Inc. (NBIX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Neurocrine Biosciences, Inc. (NBIX)

Neurocrine Biosciences, Inc. (NBIX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why

Neurocrine Biosciences: Core Business On Track, Soleno Deal Adds Risky Upside

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences, Inc. (NBIX) Q1 2026 Earnings Call Transcript

Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say

Neurocrine Biosciences (NBIX) Beats Q1 Earnings and Revenue Estimates

Видео

No Data

Пресс-релизы

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences Reports First-Quarter 2026 Financial Results

Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist